And the winner is …. Dr. Hein Coolen
Dr. Hein Coolen of Fair Medicine is the winner of the Paul Janssen Futurelab Nomination Letter 2018 for the best clinical protocol entitled ‘A phase 2 Trial of monobenzone-imiquimod (MI) therapy in combination with nivolumab for the treatment of unresectable, Stage IIIB to IVM1c Melanoma’.
Dr. Coolen developed the clinical trial protocol together with a mentor during the blended course Clinical Development of Paul Janssen Futurelab. With his proposal he won the Best Clinical Trial Protocol Challenge 2018 and the Paul Janssen Futurelab Nomination Letter. Dr. Coolen developed the protocol in collaboration with researchers and clinical-investigators in the Amsterdam UMC (AMC and VUmc) and NKI/AVL. With this nomination they can now apply for the € 500,000 ZonMw grant, which will allow them to execute the clinical trial in the Netherlands.
Hein Coolen and colleagues, the winners of the Paul Janssen Futurelab Nomination Letter 2018. From left to right: prof. dr. Rosalie Luiten (Amsterdam UMC), dr. Germaine Relyveld (NKI/AVL), Dr. Hein Coolen (Fair Medicine), Dr. Alexander van Akkooi (NKI/AVL), Dr. Marcel Bekkenk (Amsterdam, UMC). Photo by Flora Madu.
Articles from our blog
This may be interesting for you
And the winner is…… Marieke Pierik!
Dr. Marieke Pierik from the Maastricht University Medical Centre (MUMC+) is the winner of the € 500,000 ZonMw grant for the best clinical trial proposal entitled ‘Control Crohn Safe with episodic adalimumab as first line treatment trial’ also known as the CoCros studie.
Scholarships and Grant Available for 6th Edition Clinical Development Course
We are happy to announce that scholarships are again available for selected candidates from NKI/AVL and UMCs in the Netherlands. In addition, participants of the complete blended program will have the opportunity to win the PJFL nomination letter and a highly competitive ZonMw grant of €500.000 for the best clinical trial protocol in 2019. This accredited course is awarded 4.5 out of 5 stars by course participants.
Interview with Marcel Kenter in Medicines Magazine
Medicines interviewed Marcel Kenter about the Paul Janssen Futurelab initiative and the successful Clinical Development course. We have already been able to welcome over 60 graduated biomedical professionals from industry, start-ups, and academia in Asia, Europe, and the USA.